Generated by All in One SEO v4.8.9, this is an llms.txt file, used by LLMs to index the site.

# PPHI

Perhimpunan Peneliti Hati Indonesia

## Sitemaps

- [XML Sitemap](https://pbpphi.org/sitemap.xml): Contains all public & indexable URLs for this website.

## Pos

- [Community Posts](https://pbpphi.org/community-posts/) - Resources, news, advices, and commentary written by our authors
- [Wide Benefit, Less Toxic](https://pbpphi.org/wide-benefit-less-toxic/) - HCC Academy of Immunotherapy (Ina-CIT): Clinician roles to change HCC patient’s outcomes in Cancer Immunotherapy Era, conducted on 01 October 2022, 09:30 AM, at Mandarin Oriental Hotel Jakarta, which was conducted in Hybrid mode and participated by 31 HCPs offline and 7 HCPs online. In the 1st scientific session moderated by Dr. dr. Andri Sanityoso,
- [Overview PPHI Website](https://pbpphi.org/overview-pphi-website/) - Untuk memudahkan para hepatolog mencari segala informasi terkait penyakit hati, jurnal, dan update event PPHI serta untuk para anggota saling berkomunikasi, tim PPHI meluncurkan kembali situs resminya di tahun 2022 ini dengan alamat pbpphi.org. Lihat fitur apa saja yang ada dalam situs PPHI dengan menyimak video berikut: Berikut adalah cara untuk mendaftarkan diri di website
- [Indonesian consensus on systemic therapies for hepato cellular carcinoma](https://pbpphi.org/indonesian-consensus-on-systemic-therapies-for-hepato-cellular-carcinoma/) - Abstract Hepatocellular carcinoma (HCC) is a deadly cancer with a rising incidence in the last 20 years. Most patients are diagnosed late when curative treatment is no longer feasible. With the background of chronic liver disease in most patients, the management of HCC becomes more complicated, in which well-preserved liver function is a prerequisite for
- [Enhancing Interprofessional Collaboration for Improving Hepatobiliary Diseases Management](https://pbpphi.org/enhancing-interprofessional-collaboration-for-improving-hepatobiliary-diseases-management/) - "Virtual The 14th Liver Update and The Annual Scientific Meeting of Ina ASL/PPHI 2022” symposium is organized by Division of Hepatobiliary, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo National General Hospital and Indonesian Association for the Study of the Liver (Ina ASL/PPHI).
- [Virtual Liver Update 2022 - Clinical Associate Prof Tai Wai Meng David, Singapore Session](https://pbpphi.org/virtual-liver-update-2022-clinical-associate-prof-tai-wai-meng-david-singapore-session/) - Clinical Associate Prof Tai Wai Meng David was giving his presentation on Implications of Immunotherapy Data in Unresectable HCC. There were three highlights from his session:
- [GUIDELINES ](https://pbpphi.org/guidelines/) - Konsensus Hepatitis C 2003 (Ringkasan) Konsensus PPHI tentang Hepatitis C Konsensus ini berisi tentang penatalaksanaan Hepatitis C kronik, yang membahas mulai dari riwayat alamiah virus Hepatitis C, pendekatan diagnosis, perkembangan inveksi virus, hingga membahas tentang rekomendasi dan terapi. Konsensus Hepatitis B (Ringkasan) Konsensus PPHI tentang Hepatitis B Konsensus ini berisi tentang penatalaksanaan Hepatitis B kronik,
- [APASL 2020 Annual Meeting in Bali, Indonesia Drug Induced Liver Injury Symposium](https://pbpphi.org/apasl-2020-annual-meeting-in-bali-indonesia-drug-induced-liver-injury-symposium/) - Date: March 4-8, 2020City: Bali, IndonesiaPresident: Dr. Rino Gani Website : HereRegistrasi : Here Download Second Announcement : Here
- [Aksi Hepatitis: Saatnya Peduli Hepatitis. Ketahui, Cegah dan Obati!](https://pbpphi.org/aksi-hepatitis-saatnya-peduli-hepatitis-ketahui-cegah-dan-obati/) - Tingginya angka kejadian hepatitis di Indonesia dan rendahnya pengetahuan masyarakat akan penyakit ini membuat Perhimpunan Peneliti Hati Indonesia (PPHI)
- [APASL 2020 Annual Meeting in Bali, Indonesia Update](https://pbpphi.org/apasl-2020-annual-meeting-in-bali-indonesia-update/) - Date: March 4-8, 2020City: Bali, IndonesiaPresident: Dr. Rino GaniWebsite : HereRegistrasi : Here Download Second Announcement : Here
- [Basic Course of Chronic Hepatitis C and HIV/HCV Coinfection Management](https://pbpphi.org/basic-course-of-chronic-hepatitis-c-and-hiv-hcv-coinfection-management/) - Basic Course of Chronic Hepatitis C Management is an educational attempt designed for expanding the reach in hepatitis C management with focus on internist in Indonesia. An uneven distribution of knowledge on hepatitis C management possibly lead to incapable of providing proper treatment meeting high prevalence of hepatitis C is the main stating point of
- [Kampanye dan Edukasi Hari Hepatitis Sedunia](https://pbpphi.org/kampanye-dan-edukasi-hari-hepatitis-sedunia/) - Jakarta, - PT Kalbe Farma Tbk (Kalbe) bekerja sama dengan Peneliti Hati Indonesia (PPHI) mengadakan kampanye dan edukasi kesehatan
- [Lawan Hepatitis C: Kenali, Periksa, Kalahkan](https://pbpphi.org/lawan-hepatitis-c-kenali-periksa-kalahkan/) - Dalam rangka peringatan hari Hepatitis sedunia 2015 yang jatuh pada 28 Juli 2015, KEMENKES yang diwakili oleh Direktur Penanggulangan Penyakit Menular Langsung (PPML), Dr. Sigit Priohutomo, MPH, Perhimpunan Peneliti Hati Indonesia (PPHI) yang diwakili oleh Dr. dr. Rino A. Gani, SpPD-KGEH, juga Dr. Ria Syafitri EG, M.Biomed., sebagai Direktur Unit Transfusi Darah Pusat – Palang
- [Peran L-Ornithine L–Aspartate dan Asam Amino Rantai Cabang pada Ensefalopati dan Status Nutrisi dalam Sirosis Hati dengan Malnutrisi](https://pbpphi.org/peran-l-ornithine-l-aspartate-dan-asam-amino-rantai-cabang-pada-ensefalopati-dan-status-nutrisi-dalam-sirosis-hati-dengan-malnutrisi/) - Suzanna Ndraha, Irsan Hasan, Marcellus Simadibrata Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia, Rumah Sakit Cipto Mangunkusumo, Jakarta, Indonesia Abstrak Latar Belakang. Penatalaksanaan ensefalopati hepatik termasuk ensefalopati hepatik minimal (EHM) terutama ditujukan untuk menurunkan kadar amonia darah, antara lain dengan pembatasan asupan protein. Namun, pembatasan asupan protein ini akan memperburuk status gizi pada penderita
- [Artikel Umum: Kanker Saluran Empedu](https://pbpphi.org/artikel-umum-kanker-saluran-empedu/) - FAKTA Fakta: Berdasarkan Riset Kesehatan Dasar (Riskesdas) tahun 2007 kanker merupakan penyebab kematian nomor 7 di Indonesia, dan menurut statistik rumah sakit dalam Sistem Informasi Rumah Sakit (SIRS) tahun 2007 kanker hati dan saluran empedu intrahepatik menempati urutan ketiga pada pasien rawat inap di seluruh RS di Indonesia. (i)Angka kejadian kanker saluran empedu tertinggi di dunia
- [PEPERANGAN DUNIA MELAWAN KANKER](https://pbpphi.org/peperangan-dunia-melawan-kanker/) - The International Agency for Research on Cancer (IARC), perkumpulan spesialis kanker World Health Organization (WHO), baru-baru ini meluncurkan laporan kanker dunia 2014,
- [Video Animasi Hepatitis C PPHI](https://pbpphi.org/video-animasi-hepatitis-c-pphi/) - Perhimpunan Peneliti Hati Indonesia (PPHI) meluncurkan video animasi pertama berisi informasi tentang penyakit Hepatitis C
- [Jangan Takut Dulu, Begini Cara Penyakit Hepatitis Bisa Menular](https://pbpphi.org/jangan-takut-dulu-begini-cara-penyakit-hepatitis-bisa-menular/) - Jakarta – Hepatitis berasal dari kata hepar (hati) dan titis (radang). Penyakit radang hati ini tidak hanya disebabkan oleh virus
- [Pola Mutasi Resistensi terhadap Analog Nukleosida Virus Hepatitis B pada Pengidap Kronis yang Belum Mendapatkan Terapi](https://pbpphi.org/pola-mutasi-resistensi-terhadap-analog-nukleosida-virus-hepatitis-b-pada-pengidap-kronis-yang-belum-mendapatkan-terapi/) - Julwan Pribadi 1), Rino Alvani Gani 2), Ari Fahrial Syam 3), Cosmas Rinaldi Lesmana 2), Budiman Bela 4), Siti Setiati 5), Hartiyowidi Yuliawuri 4), Anugrah Dwi Handayu 2) 1) Program Studi Pendidikan Profesi Dokter Spesialis-II/Konsultan Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia, Kekhususan Gastroentero-Hepatologi.2)Divisi Hepatologi, Departemen Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia.3)Divisi Gastroenterologi, Departemen Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia.4)Institute of Human Virology and
- [Artikel Umum: Batu Empedu](https://pbpphi.org/artikel-umum-batu-empedu/) - FAKTA: Kira-kira 700.000 kolesistektomi (pengankatan kantong empedu) disebabkan oleh batu empedu (i)Setiap tahunnya komplikasi batu empedu menyebabkan 3000 kematian (0,12% dari seluruh angka kematian) (i)Rasio penderita batu empedu pada wanita terhadap pria adalah 3:1 pada usia dewasa reproduktif, dan berkurang menjadi 2:1 pada usia diatas 70 tahun (ii)Prevalensi kejadian batu empedu tertinggi terjadi pada suku
- [Wajib tau !! Ini Penjelasan Tentang Hepatitis A](https://pbpphi.org/wajib-tau-ini-penjelasan-tentang-hepatitis-a/) - Hepatitis A merupakan penyakit menular yang disebabkan oleh virus hepatitis A. Infeksi virus hepatitis A mengakibatkan peradangan pada hati. Virus hepatitis A ditularkan melalui makanan atau minuman yang terkontaminasi virus hepatitis A. Virus hepatitis A berasal dari tinja orang yang menderita hepatitis A. Karena hygiene yang tidak bagus, sehingga makanan dan minuman dapat terkontaminasi oleh

## Laman

- [Home](https://pbpphi.org/)
- [Privacy Policy](https://pbpphi.org/privacy-policy-2/) - How and why we process your personal data We hereby inform you that your personal data, including name and surname, job title and contact details (including email address, phone number, fax number, postal address) and also information provided in Curriculum Vitae if required, will be collected for purposes connected with the PPHI website.We process your
- [Struktur Organisasi](https://pbpphi.org/struktur-organisasi/) - Susunan Pengurus Besar Perhimpunan Peneliti Hati Indonesia Organization Committee of Ina ASL Periode 2019- 2022 Penasehat Advisors Prof. dr. H. Ali Sulaiman, Ph.D, Sp.PD-KGEH, FACG Prof. dr. H. Nurul Akbar, Sp.PD-KGEH Prof. dr. Laurentius A. Lesmana, Ph.D, Sp.PD-KGEH, FACP, FACG dr. Unggul Budihusodo, Sp.PD-KGEH Prof.Dr. dr. Rino Alvani Gani, Sp.PD-KGEH Ketua Umum President Dr.
- [Cabang PPHI](https://pbpphi.org/cabang-pphi/) - so far PPHI has 19 branches spread all over Indonesia, and they are located in: 1. Nanggroe Aceh Darussalam Chairman: Dr. Fauzy Yusuf, SpPD, KGEHDivision of Gastroentero-Hepatology, Department of Internal Medicine,Medical Faculty University of Syiah Kuala/BPK-Dr. Zainoel Abidin General Hospital,Jl. Tengku Daud Beureueh No. 108, Banda Aceh 23116, Indonesia,Telp. +62651-26090 Fax. +62651-26090, 47646, 23823Email: fozi_ysf63@yahoo.co.id
- [Kontak](https://pbpphi.org/kontak/) - Send a Message +6221 – 391 6770 pphi_org@yahoo.com Gedung Wisma Bhakti Mulya 6th Floor Suite 601 Jl. Kramat Raya No. 160 Jakarta Pusat 10430, Indonesia
- [Sample Page](https://pbpphi.org/sample-page/) - This is an example page. It's different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this: Hi there! I'm a bike messenger
- [Members Sidebar Left](https://pbpphi.org/members-sidebar-left/)
- [Members Sidebar Right](https://pbpphi.org/members-sidebar-right/)
- [Homepage 2](https://pbpphi.org/home-2/)
- [Sites](https://pbpphi.org/sites/)
- [Block Unit Test](https://pbpphi.org/block-unit-test/) - Donec id elit non mi porta gravida at eget metus. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec ullamcorper nulla non metus auctor fringilla. Heading One Heading Two Heading Three Heading Four Heading Five Heading Six Preformatted Block The Road Not Taken, by Robert FrostTwo roads diverged in a yellow
- [Icons](https://pbpphi.org/all-icons/) - Evericons You can preview all icons here. Preview Evericons FontAwesome All FontAwesome (v 4.7) icons are included. Preview FontAwesome 4.7
- [Discover](https://pbpphi.org/discover/)

## Template-ku

- [Elementor Archive Perpustakaan](https://pbpphi.org/?elementor_library=elementor-archive-perpustakaan) - Title Categories Update Date Download Konsensus Nasional Penatalaksanaan Hepatitis B di Indonesia1 173 downloads Other treatment 01/07/2026 Download Konsensus Nasional Penatalaksanaan Hepatitis C pada Penyakit Ginjal Kronik di Indonesia1 75 downloads Other treatment 23/06/2026 Download Panduan Pemberian Terapi Sistemik untuk Kasinoma Sel Hati: Sebuah Panduan Praktis untuk Klinis1 65 downloads Other treatment 18/02/2026 Download Pedoman
- [Elementor Archive #4255](https://pbpphi.org/?elementor_library=elementor-archive-4255) - Artikel Populer:
- [Default Kit](https://pbpphi.org/?elementor_library=default-kit)
- [Discover](https://pbpphi.org/?elementor_library=discover)
- [Homepage 2](https://pbpphi.org/?elementor_library=homepage-2)
- [Homepage](https://pbpphi.org/?elementor_library=homepage)
- [Default Kit](https://pbpphi.org/?elementor_library=default-kit-2)

## Downloads

- [Konsensus Nasional Penatalaksanaan Hepatitis B di Indonesia](https://pbpphi.org/download/konsensus-nasional-penatalaksanaan-hepatitis-b-di-indonesia/) - Judul : Konsensus Nasional Penatalaksanaan Hepatitis B di Indonesia ISBN : Masih dalam proses Penulis : Ketua: Dr. dr. Juferdy Kurniawan, SpPD, K-GEH, FACG, FINASIM Anggota: Prof. Dr. dr. Rino Alvani Gani, SpPD, K-GEH, FINASIM • Dr. dr. Irsan Hasan, SpPD, K-GEH, FACG, FINASIM • Dr. dr. Andri Sanityoso Sulaiman, SpPD, K-GEH, FINASIM • Dr.
- [Konsensus Nasional Penatalaksanaan Hepatitis C pada Penyakit Ginjal Kronik di Indonesia](https://pbpphi.org/download/konsensus-nasional-penatalaksanaan-hepatitis-c-pada-penyakit-ginjal-kronik-di-indonesia/) - Judul: Konsensus Nasional Penatalaksanaan Hepatitis C pada Penyakit Ginjal Kronik di Indonesia ISBN: masih dalam proses Penulis: Dr. dr. Andri Sanityoso, SpPD, K-GEH, FINASIM, Dr. dr. Pringgodigdo Nugroho, SpPD, K-GH, FINASIM, dr. Ni Made Hustrini, SpPD, K-GH, PhD, dr. Pitt Akbar, SpPD Ukuran: 15 x 23 cm SINOPSIS Disusun oleh Perhimpunan Peneliti Hati Indonesia (PPHI)
- [Panduan Pemberian Terapi Sistemik untuk Kasinoma Sel Hati: Sebuah Panduan Praktis untuk Klinis](https://pbpphi.org/download/panduan-pemberian-terapi-sistemik-untuk-kasinoma-sel-hati-sebuah-panduan-praktis-untuk-klinis/) - Judul: Panduan Pemberian Terapi Sistemik untuk Kasinoma Sel Hati: Sebuah Panduan Praktis untuk Klinisi ISBN: masih dalam proses Penulis: Irsan Hasan, Imelda Maria Loho, Lutfie, Kevin Tjoa Ukuran: 15 x 23 cm SINOPSIS Karsinoma sel hati (KSH) merupakan salah satu penyebab kematian tertinggi akibat kanker dan tetap menjadi tantangan besar dalam layanan kesehatan di Indonesia.
- [Pedoman Nasional Pelayanan Kedokteran (PNPK) Tata Laksana Karsinoma Sel Hati pada Dewasa tahun 2022](https://pbpphi.org/download/pedoman-nasional-pelayanan-kedokteran-pnpk-tata-laksana-karsinoma-sel-hati-pada-dewasa-tahun-2022/)
- [Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma](https://pbpphi.org/download/atezolizumab-plus-bevacizumab-followed-by-curative-conversion-abc-conversion-in-patients-with-unresectable-tace-unsuitable-intermediate-stage-hepatocellular-carcinoma/)
- [The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab](https://pbpphi.org/download/the-prognostic-value-of-neutrophil-to-lymphocyte-ratio-and-platelet-to-lymphocyte-ratio-in-patients-with-hepatocellular-carcinoma-receiving-atezolizumab-plus-bevacizumab/)
- [Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis](https://pbpphi.org/download/safety-and-efficacy-of-atezolizumab-plus-bevacizumab-in-elderly-patients-with-hepatocellular-carcinoma-a-multicenter-analysis/)
- [IMbrave150: Exploratory efficacy and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study](https://pbpphi.org/download/imbrave150-exploratory-efficacy-and-safety-in-patients-with-unresectable-hepatocellular-carcinoma-hcc-treated-with-atezolizumab-beyond-radiological-progression-until-loss-of-clinical-benefit-in-a-g/)
- [IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)](https://pbpphi.org/download/imbrave150-updated-overall-survival-os-data-from-a-global-randomized-open-label-phase-iii-study-of-atezolizumab-atezo-bevacizumab-bev-versus-sorafenib-sor-in-patients-pts-with-unresecta/)
- [Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240 A Randomized Double-Blind Phase III Trial](https://pbpphi.org/download/pembrolizumab-as-second-line-therapy-in-patients-with-advanced-hepatocellular-carcinoma-in-keynote-240-a-randomized-double-blind-phase-iii-trial/)
- [Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib](https://pbpphi.org/download/efficacy-and-safety-of-nivolumab-plus-ipilimumab-in-patients-with-advanced-hepatocellular-carcinoma-previously-treated-with-sorafenib/)
- [Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma](https://pbpphi.org/download/tremelimumab-plus-durvalumab-in-unresectable-hepatocellular-carcinoma/)
- [Sorafenib in Advanced Hepatocellular Carcinoma](https://pbpphi.org/download/sorafenib-in-advanced-hepatocellular-carcinoma/)
- [REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset](https://pbpphi.org/download/reflect-a-phase-3-trial-comparing-efficacy-and-safety-of-lenvatinib-to-sorafenib-for-the-treatment-of-unresectable-hepatocellular-carcinoma-an-analysis-of-japanese-subset/)
- [A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion](https://pbpphi.org/download/a-novel-treatment-strategy-for-patients-with-intermediate-stage-hcc-who-are-not-suitable-for-tace-upfront-systemic-therapy-followed-by-curative-conversion/)
- [New treatment paradigm with systemic therapy in intermediate‑stage hepatocellular carcinoma](https://pbpphi.org/download/new-treatment-paradigm-with-systemic-therapy-in-intermediate‑stage-hepatocellular-carcinoma/)
- [Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial](https://pbpphi.org/download/atezolizumab-plus-bevacizumab-versus-sorafenib-for-unresectable-hepatocellular-carcinoma-results-from-older-adults-enrolled-in-the-imbrave150-randomized-clinical-trial/)
- [Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study](https://pbpphi.org/download/atezolizumab-plus-bevacizumab-versus-sorafenib-in-the-chinese-subpopulation-with-unresectable-hepatocellular-carcinoma-phase-3-randomized-open-label-imbrave150-study/)
- [Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma](https://pbpphi.org/download/updated-efficacy-and-safety-data-from-imbrave150-atezolizumab-plus-bevacizumab-vs-sorafenib-for-unresectable-hepatocellular-carcinoma/)
- [Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma](https://pbpphi.org/download/atezolizumab-plus-bevacizumab-in-unresectable-hepatocellular-carcinoma/)
- [Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma](https://pbpphi.org/download/current-landscape-of-immune-checkpoint-inhibitor-therapy-for-hepatocellular-carcinoma/)
- [Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges](https://pbpphi.org/download/immune-checkpoint-inhibitors-in-hepatocellular-carcinoma-current-progresses-and-challenges/)
- [Immune Checkpoint Inhibitors in the Treatment of HCC](https://pbpphi.org/download/immune-checkpoint-inhibitors-in-the-treatment-of-hcc/)
- [Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date](https://pbpphi.org/download/combination-antiangiogenic-and-immunotherapy-for-advanced-hepatocellular-carcinoma-evidence-to-date/)
- [Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview](https://pbpphi.org/download/immune-checkpoint-inhibitors-in-hepatocellular-carcinoma-an-overview/)
- [Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment](https://pbpphi.org/download/immune-checkpoint-inhibitors-in-hepatocellular-cancer-current-understanding-on-mechanisms-of-resistance-and-biomarkers-of-response-to-treatment/)
- [Combination Cancer Immunotherapy in Hepatocellular Carcinoma](https://pbpphi.org/download/combination-cancer-immunotherapy-in-hepatocellular-carcinoma/)
- [Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?](https://pbpphi.org/download/novel-immunotherapy-combinations-in-clinical-trials-for-hepatocellular-carcinoma-will-they-shape-the-future-treatment-landscape/)
- [Clinically approved combination immunotherapy: Current status, limitations, and future perspective](https://pbpphi.org/download/clinically-approved-combination-immunotherapy-current-status-limitations-and-future-perspective/)
- [Immunotherapy for advanced hepatocellular carcinoma a focus on special subgroups](https://pbpphi.org/download/immunotherapy-for-advanced-hepatocellular-carcinoma-a-focus-on-special-subgroups/)
- [Combination therapy for advanced hepatocellular carcinoma do we see the light at the end of the tunnel](https://pbpphi.org/download/combination-therapy-for-advanced-hepatocellular-carcinoma-do-we-see-the-light-at-the-end-of-the-tunnel/)
- [Advances in immunotherapy for hepatocellular carcinoma](https://pbpphi.org/download/advances-in-immunotherapy-for-hepatocellular-carcinoma/)
- [Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects](https://pbpphi.org/download/immunotherapy-for-hepatocellular-carcinoma-current-status-and-future-prospects/)
- [Hepatocellular carcinoma](https://pbpphi.org/download/hepatocellular-carcinoma/)
- [Management of Hepatocellular Carcinoma in Japan JSH Consensus Statements and Recommendations 2021 Update](https://pbpphi.org/download/management-of-hepatocellular-carcinoma-in-japan-jsh-consensus-statements-and-recommendations-2021-update/)
- [Systemic treatment of hepatocellular carcinoma: An EASL position paper](https://pbpphi.org/download/systemic-treatment-of-hepatocellular-carcinoma-an-easl-position-paper/)
- [2022 Update of BCLC Treatment Algorithm of HCC: What's New for Interventional Radiologists](https://pbpphi.org/download/2022-update-of-bclc-treatment-algorithm-of-hcc-whats-new-for-interventional-radiologists/)
- [ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://pbpphi.org/download/esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up/)
- [APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19](https://pbpphi.org/download/apasl-practical-recommendations-for-the-management-of-hepatocellular-carcinoma-in-the-era-of-covid-19/)
- [Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology](https://pbpphi.org/download/hepatobiliary-cancers-version-2-2021-nccn-clinical-practice-guidelines-in-oncology/)

## Kategori

- [NA](https://pbpphi.org/category/na/)
- [Artikel](https://pbpphi.org/category/artikel/)
- [Research](https://pbpphi.org/category/research/)
- [Video](https://pbpphi.org/category/artikel/video/)
- [Kegiatan](https://pbpphi.org/category/kegiatan/)
- [Literatur](https://pbpphi.org/category/artikel/literatur/)

## Tag

- [DR.Irsan](https://pbpphi.org/tag/dr-irsan/)
- [hepatitis](https://pbpphi.org/tag/hepatitis/)
- [hepatitis sedunia](https://pbpphi.org/tag/hepatitis-sedunia/)
- [kampanye](https://pbpphi.org/tag/kampanye/)
- [fight](https://pbpphi.org/tag/fight/)
- [health](https://pbpphi.org/tag/health/)
- [news](https://pbpphi.org/tag/news/)
- [hari hepatitis sedunia](https://pbpphi.org/tag/hari-hepatitis-sedunia/)
- [hepatitis a hati](https://pbpphi.org/tag/hepatitis-a-hati/)
- [virus](https://pbpphi.org/tag/virus/)
- [Research](https://pbpphi.org/tag/research/)

## Categories

- [Perpustakaan](https://pbpphi.org/download-category/perpustakaan/)
- [Guideline](https://pbpphi.org/download-category/guideline/)
- [Immunotherapy in HCC](https://pbpphi.org/download-category/immunotherapy-in-hcc/)
- [AtezoBev in advance HCC](https://pbpphi.org/download-category/atezobev-in-advance-hcc/)
- [AtezoBev in Intermediate HCC](https://pbpphi.org/download-category/atezobev-in-intermediate-hcc/)
- [Other treatment](https://pbpphi.org/download-category/other-treatment/)